MRK

Merck & Co. Inc. (NYSE: MRK) has decided to discontinue the development of its COVID-19 vaccine candidates after its clinical…

Merck (NYSE: MRK) announced the acquisition of privately-held biopharma company OncoImmune for an upfront payment of $425 million in cash…

Merck & Co. Inc. (NYSE: MRK) Q3 2020 earnings call dated Oct. 27, 2020 Corporate Participants: Peter Dannenbaum — Vice President, Investor…

Merck & Co., Inc. (NYSE: MRK) reported stronger than expected earnings and sales for the third quarter of 2020. The…

Merck & Co., Inc. (NYSE: MRK) Q2 2020 earnings call dated July 31, 2020 Corporate Participants: Peter Dannenbaum — Vice President of…

Merck (NYSE: MRK) reported an 8% drop in second quarter sales, reflecting the negative impact of COVID-19. However, sales of…

Merck & Co (MRK) Q1 2020 earnings call dated April 28, 2020 Corporate Participants: Peter Dannenbaum — Vice President of Investor Relations…

Merck (NYSE: MRK) today reported first quarter financial results for the period ended March 31, 2020. On GAAP basis, first…

Merck & Co Inc (NYSE: MRK) Q4 2019 Earnings Conference Call February 05, 2020 Corporate Participants: Peter Dannenbaum — Vice President of…

Merck & Co., Inc. (NYSE: MRK) reported stronger than expected earnings for the fourth quarter of 2019. However, the company’s…